🔎 Trials Near Me

Почетна › Кронова болест › Мисури

Клинички испитувања за Кронова болест во Мисури

21 студии за Кронова болест бараат учесници на локации во Мисури.

Градови во Мисури

Официјален текст на студијата (англиски)

Extension Study of Long-term Safety and Efficacy of Tulisokibart in Participants With Crohn's Disease or Ulcerative Colitis (MK-7240-011)

  • BVL Research - Kansas ( Site 0292), Liberty
Се регрутираФаза 3
Сите возрасти · Сите полови · Ажурирано 2.10.2026 · NCT06651281

A Study to Evaluate the Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderate to Severe Crohn's Disease (MK-7240-008)

  • Mid-America GI Clinical Research ( Site 5130), Kansas City
  • BVL Research - Kansas ( Site 5099), Liberty
  • Washington University School of Medicine ( Site 5058), St Louis
Се регрутираФаза 3
Возраст од 16 до 80 · Сите полови · Ажурирано 2.10.2026 · NCT06430801

Study of Advanced Therapies for the Treatment of Adult Participants With Moderately to Severely Active Crohn's Disease or Ulcerative Colitis

  • Specialists In Gastroenterology /ID# 283939, St Louis
Се регрутираФаза 2
Возраст од 18 до 75 · Сите полови · Ажурирано 2.10.2026 · NCT07697456

A Study of Vedolizumab in Adults With Ulcerative Colitis (UC) or Crohn's Disease (CD) in the Community Setting

  • SSM Health Medical Group, Bridgeton
  • GI Associates Research, LLC, Columbia
  • Mid America Gastro Intestinal Consultants, Kansas City
  • и уште 1
Се регрутираФаза 4
Возраст од 18 до 80 · Сите полови · Ажурирано 30.9.2026 · NCT06581328

Study of Targeted Therapies for the Treatment of Adult Participants With Moderate to Severe Crohn's Disease

  • GI Associates Research, LLC /ID# 267433, Columbia
  • Bvl Research /ID# 265870, Liberty
  • Washington University /ID# 266938, St Louis
Се регрутираФаза 2
Возраст од 18 до 75 · Сите полови · Ажурирано 25.9.2026 · NCT06548542

A Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Moderately to Severely Active Crohn's Disease

  • BVL Clinical Research, Liberty
Се регрутираФаза 2
Возраст од 18 до 75 · Сите полови · Ажурирано 25.9.2026 · NCT06233461

Mirikizumab and Tirzepatide Administered in Adult Participants With Moderately to Severely Active Crohn's Disease and Obesity or Overweight

  • Washington University School of Medicine, St Louis
Се регрутираФаза 3
Возраст од 18 до 70 · Сите полови · Ажурирано 24.9.2026 · NCT06937099

Testing an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVO

  • Siteman Cancer Center at Saint Peters Hospital, City of Saint Peters
  • Siteman Cancer Center at West County Hospital, Creve Coeur
  • University Health Truman Medical Center, Kansas City
  • и уште 6
Се регрутираФаза 1
Возраст 18 и постари · Сите полови · Ажурирано 23.9.2026 · NCT03816345

An Induction Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Crohn's Disease

  • BVL Clinical Research-Site Number: 8400005, Liberty
  • Washington University School of Medicine-Site Number: 8400075, St Louis
  • Gateway Gastroenterology-Site Number: 8400097, St Louis
Се регрутираФаза 3
Возраст од 16 до 80 · Сите полови · Ажурирано 23.9.2026 · NCT07184931

A Maintenance Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Crohn's Disease

  • BVL Clinical Research-Site Number: 8400005, Liberty
  • Gateway Gastroenterology-Site Number: 8400097, St Louis
Се регрутираФаза 3
Возраст од 16 до 80 · Сите полови · Ажурирано 23.9.2026 · NCT07184944

A Phase 2 Study to Evaluate MORF-057 in Adults With Moderately to Severely Active Crohn's Disease

  • SSM Health DePaul Hospital- St. Louis, Bridgeton
Се регрутираФаза 2
Возраст од 18 до 85 · Сите полови · Ажурирано 22.9.2026 · NCT06226883

A Master Protocol (IIBD): A Study of Multiple Drugs in Adults With Ulcerative Colitis or Crohn's Disease

  • KAD Clinical Research, St Louis
Се регрутираФаза 2
Возраст од 18 до 80 · Сите полови · Ажурирано 22.9.2026 · NCT07483073

A Master Protocol (AMAZ): A Study of Mirikizumab (LY3074828) in Pediatric Participants With Ulcerative Colitis or Crohn's Disease (SHINE-ON)

  • Washington University School of Medicine, St Louis
Се регрутираФаза 3
Возраст од 2 до 19 · Сите полови · Ажурирано 22.9.2026 · NCT04844606

A Study of LY4395089 and Mirikizumab (LY3074828) Given Together and Mirikizumab (Alone) in Adults With Crohn's Disease

  • KAD Clinical Research, St Louis
Се регрутираФаза 2
Возраст од 18 до 80 · Сите полови · Ажурирано 22.9.2026 · NCT07483099

A Study of Vedolizumab Intravenous (IV) and Adalimumab or Vedolizumab and Ustekinumab in Adults With Crohn's Disease

  • Mid-America Gastro-Intestinal Consultants, Kansas City
  • BVL Clinical Research, Liberty
  • Washington University School of Medicine, St Louis
Се регрутираФаза 4
Возраст од 18 до 70 · Сите полови · Ажурирано 9.9.2026 · NCT06045754

DB-3Q for the Treatment of Medically Refractory Crohn's Disease

  • Washington University, St. Louis, St Louis
Се регрутираФаза 2
Возраст од 18 до 75 · Сите полови · Ажурирано 1.9.2026 · NCT07625293

Moving Beyond Inflammation as a Therapeutic Target for Crohn's Disease

  • Washington University School of Medicine, St Louis
Се регрутираФаза 2
Возраст од 18 до 80 · Сите полови · Ажурирано 5.6.2026 · NCT06976853

A Study to Investigate Efficacy and Safety of SAR442970 in Patients With Crohn's Disease

  • Investigational Site Number: 8400013, St Louis
Се регрутираФаза 2
Возраст од 18 до 75 · Сите полови · Ажурирано 27.3.2026 · NCT06958536

A Phase 2 Study to Evaluate Therapies for Inflammatory Bowel Disease

  • Mirador Therapeutics Selected Site, Bridgeton
  • Mirador Therapeutics Selected Site, Kansas City
  • Mirador Therapeutics Selected Site, Liberty
Се регрутираФаза 2
Возраст од 18 до 80 · Сите полови · Ажурирано 12.3.2026 · NCT07113522

Treatment of Moderate to Severe Refractory Crohn's Disease

  • Washington University in St. Louis, St Louis
Се регрутираФаза 1/2
Возраст од 18 до 65 · Сите полови · Ажурирано 10.12.2025 · NCT06721962

Development of a Novel Endoscopic Index and Patient-reported Outcome Measure for Clinical Trials in Participants With Permanent Ileostomy

  • Washington University in St Louis School of Medicine, St Louis
Се регрутираНабљудувачка студија
Возраст 18 и постари · Сите полови · Ажурирано 12.11.2025 · NCT06670638

Од ClinicalTrials.gov, податоци преземени 5.10.2026. Секоја студија ги поставува своите услови за вклучување; тимот на студијата одлучува кој може да учествува.